Related by context. All words. (Click for frequent words.) 77 KRAS mutations 74 EGFR mutation 72 K ras mutations 71 gefitinib 71 BRAF mutation 70 heavily pretreated 70 KRAS mutation 69 BRAF mutations 68 activating mutations 68 prostate cancer CaP 68 histologies 68 EGFR inhibitors 67 mCRC patients 67 metastatic RCC 67 T#I [002] 67 KIT mutations 67 lymph node metastases 66 KRAS gene 66 HER2 positive metastatic breast 66 ERBB2 66 K ras 66 EGFR gene 66 tyrosine kinase inhibitors 66 MGUS 66 EGFR tyrosine kinase inhibitors 66 epithelial tumors 66 NNRTI resistance 66 pCR 66 HER2 positive cancers 66 FLT3 66 pancreatic adenocarcinoma 66 adenocarcinomas 65 medullary thyroid cancer 65 TOP2A 65 advanced adenomas 65 EpCAM 65 missense mutations 65 HNSCC 65 KRAS status 65 KRAS wild 65 FGFR2 65 familial ALS 65 genetic polymorphisms 65 micrometastases 65 TTR gene 65 hepatocellular carcinomas 65 EGFR mutant 65 p# mutations 65 KRAS mutations occur 65 polymorphisms 65 PARP inhibition 65 T#I mutation 65 ErbB2 positive 65 GBM tumors 65 mutated KRAS gene 65 familial pancreatic cancer 65 standard chemotherapy regimens 65 castration resistant prostate cancer 65 HBeAg positive 64 EGFr 64 somatic mutations 64 metastatic renal cell carcinoma 64 NSCLC 64 liver metastases 64 KRAS oncogene 64 HER2 overexpression 64 carcinoid 64 GSTP1 64 dasatinib 64 chronic lymphocytic leukemia CLL 64 renal cell carcinomas 64 malignant lesions 64 cetuximab 64 prostate carcinoma 64 EBV infection 64 PTPN# 64 PTEN mutations 64 BRAF V#E mutation 64 taxane therapy 64 breast carcinoma 64 distant metastasis 64 PCa 64 alkaline phosphatase ALP 64 prostate adenocarcinoma 64 K ras mutation 64 glioblastoma tumors 64 GISTs 64 TCF#L# 64 gastric cancers 63 KRAS 63 BRCA1 mutations 63 GSTM1 63 molecular subtypes 63 promoter methylation 63 myeloproliferative disorders 63 gefitinib Iressa 63 lymph node involvement 63 HBeAg negative 63 seliciclib 63 BRCA deficient 63 imatinib Gleevec 63 differentiated thyroid 63 IGF 1R 63 metastatic lesions 63 ABCB1 63 metastatic melanomas 63 MMP inhibitors 63 GPNMB 63 sporadic ALS 63 ALK mutations 63 clusterin 63 trastuzumab Herceptin ® 63 lymphoid malignancies 63 recurrent glioblastoma multiforme 63 poor metabolizers 63 bendamustine 63 JAK2 63 mRCC 63 HIV HCV coinfected 63 hypermethylation 63 adjuvant chemotherapy 63 TGFBR1 * 6A 63 HCV infections 63 basal cell nevus syndrome 63 genotypes 63 erlotinib 63 squamous cell histology 63 heterozygous 63 HER2 amplification 63 receptor tyrosine kinase inhibitor 63 HER2 expression 63 HCV infected 63 IGF IR 63 squamous histology 63 genotypic resistance 63 HGPIN 63 CC genotype 63 hypermethylated 62 chromosomal rearrangement 62 activating mutation 62 causal variants 62 Doxil ® 62 HLA DR 62 MAGE A3 62 IDH1 mutation 62 untreated metastatic melanoma 62 EGFR mutation positive 62 K RAS 62 JAK inhibitors 62 VIPR2 62 tumor subtypes 62 GBA mutations 62 nonmetastatic 62 M#V mutation 62 relapsed SCLC 62 antiangiogenic therapy 62 predictive biomarkers 62 MSH2 62 renal tumors 62 serous ovarian cancer 62 Gleevec resistant 62 EGFRvIII 62 VEGFR2 62 distant metastases 62 benign moles 62 basal cell carcinoma BCC 62 genotype 62 HCV genotype 62 miR #a [001] 62 posaconazole 62 heterozygotes 62 HER2/neu 62 myeloproliferative diseases 62 p# biomarker 62 bladder cancers 62 Clusterin 62 V#F mutation 62 leukemia CLL 62 alpha synuclein gene 62 subtypes 62 HER2 positive tumors 62 squamous cell lung cancer 62 mutated K ras 62 gene variants 62 virologic responses 62 CIN2 + 62 mtDNA mutations 62 neoplasia 62 germline mutations 62 lung metastasis 62 complete cytogenetic response 62 neoplasms 62 imatinib resistant 62 subclinical hyperthyroidism 62 B7 H3 62 genetic variants 62 PIK3CA 62 WT1 62 NPM1 62 underwent resection 62 T2DM 62 chemoresistant 62 nonmelanoma skin cancers 62 lymph node metastasis 62 EphA2 62 xenograft models 62 medically inoperable 62 CYP#C# [001] 62 stage IIIB 62 heavily pretreated patients 62 susceptibility loci 62 BRAF V#E 62 neuroblastoma tumors 62 MAPK pathway 62 coinfected patients 62 BCR ABL mutations 62 poorer prognosis 62 SPINK1 62 LTBI 62 colorectal tumors 62 EGFR 62 trastuzumab 62 TMEM#B 62 EGFR activating mutations 62 rs# [002] 62 colorectal liver metastases 62 ADPKD 62 EGFR mutation status 62 adjuvant therapy 62 histone deacetylases 62 pancreatic neuroendocrine tumors 61 predictive biomarker 61 HPV# 61 C#Y 61 colorectal carcinoma 61 myelofibrosis polycythemia vera 61 advanced adenoma 61 axitinib 61 premalignant lesions 61 HER3 61 hepatocellular carcinoma 61 EGFR inhibition 61 completely resected 61 ovarian carcinoma 61 neuroendocrine tumors 61 cMET 61 EUS FNA 61 ZNF# 61 castrate resistant prostate cancer 61 Leydig cell 61 LRAT 61 methylation patterns 61 gastric carcinoma 61 MGd 61 normal karyotype 61 preoperative chemotherapy 61 KRAS mutant tumors 61 enzastaurin 61 ependymomas 61 recurrent NSCLC 61 MLH1 61 K#N 61 IL#B 61 K ras gene 61 E#F# 61 bevacizumab Avastin ® 61 mesotheliomas 61 elevated CRP 61 breast cancer subtypes 61 trans retinoic acid 61 prognostic markers 61 genomic alterations 61 KRAS mutant 61 chemosensitivity 61 gemcitabine Gemzar 61 gastric adenocarcinoma 61 cisplatin resistant 61 FGFR1 61 tumor histology 61 atypical hyperplasia 61 PKCi 61 FDG PET 61 HAAH 61 APOL1 61 neoadjuvant chemotherapy 61 proto oncogene 61 pDCs 61 essential thrombocythemia 61 HER2 receptor 61 erlotinib Tarceva ® 61 BRCA2 carriers 61 advanced neoplasia 61 CXCR4 61 TRAF1 C5 61 tumor recurrence 61 lymphomas 61 gastrointestinal stromal tumors GISTs 61 EGFR TKIs 61 JAK3 61 refractory CLL 61 TP# mutations 61 relapsed MM 61 HGS ETR1 61 imatinib 61 trabectedin 61 susceptibility genes 61 carcinoids 61 mutations 61 MYCN amplification 61 hepatoma 61 breast carcinomas 61 EGFR TKI 61 haematopoietic 61 contralateral breast 61 TNF α 61 CLL cells 61 splice variants 61 Li Fraumeni 61 microdeletions 61 prostate cancer CRPC 61 genetic loci 61 BRCA mutations 61 CYT# potent vascular disrupting 61 bortezomib 61 seronegative 61 TNF blocker therapy 61 androgen independent 61 gene polymorphisms 61 EGF receptor 61 CDK4 61 locoregional recurrence 61 endocrine therapies 61 prior chemotherapy regimens 61 seropositivity 61 nonsmall cell lung cancer 60 oncoproteins 60 idiopathic myelofibrosis 60 lymphocytosis 60 imatinib therapy 60 metastases 60 Immunohistochemical analysis 60 colorectal carcinomas 60 olaparib 60 #q# [001] 60 c MYC 60 AT1R 60 subgroup analyzes 60 curative resection 60 gene amplification 60 sarcosine 60 cyclin E 60 gastrointestinal stromal tumors 60 EGFR protein 60 mTOR inhibitors 60 kinase inhibition 60 VKORC1 60 nonalcoholic steatohepatitis NASH 60 HuLuc# 60 leukaemias 60 stage IIIb IV 60 neoplastic 60 precursor lesions 60 taxane chemotherapy 60 sCJD 60 miRNA genes 60 BRAF gene 60 HCV genotypes 60 INCB# [003] 60 hepatocellular cancer 60 endometrial cancers 60 osteosarcomas 60 Subgroup analyzes 60 pituitary adenomas 60 biologic pathways 60 NSCLC tumors 60 pT2 60 relapsed ovarian cancer 60 resectable 60 adecatumumab 60 recurrent GBM 60 H pylori 60 bone metastasis 60 genotypic 60 HER2 positive 60 drug metabolizing enzymes 60 follicular lymphoma 60 coinfected 60 metastatic neuroendocrine tumors 60 molecular biomarkers 60 NF1 60 hepatocellular carcinoma HCC 60 PDGFR 60 anthracycline containing 60 gene rearrangements 60 clade B 60 loci 60 lymphoma subtypes 60 occult metastases 60 metastatic renal cell 60 p# mutation 60 sarcomatoid 60 HGS ETR2 60 TGF β 60 elevated LDH 60 EGFR HER2 60 tumor necrosis 60 taxane resistant 60 BRCA2 mutation 60 HCV infection 60 renal carcinoma 60 NAFLD 60 sorafenib Nexavar 60 MET amplification 60 papillary renal cell carcinoma 60 EGFR expression 60 microRNA expression 60 Epidermal Growth Factor Receptor 60 histological subtype 60 ErbB2 60 gene loci 60 TKIs 60 anti JCV antibodies 60 basal cell carcinomas 60 circulating EPCs 60 Gag polymorphisms 60 Wwox 60 HPV subtypes 60 EpCAM expression 60 follicular lymphoma FL 60 TEAEs 60 autoantibodies 60 colorectal neoplasia 60 invasive carcinomas 60 CYP#C# [002] 60 squamous 60 K#R [002] 60 HER2 negative 60 ApoE4 60 Myelodysplastic syndromes MDS 60 nonresponders 60 viral kinetics 60 CMV disease 60 hormone receptor negative 60 ERCC1 60 PSADT 60 Her2/neu 60 S#A# [002] 60 BRCA2 mutations 60 HDAC inhibitors 60 diabetic nephropathy 60 nucleoside analogues 60 pertuzumab 60 IDH1 60 XL# inhibits 60 GIST tumors 60 JAK2 gene 60 decitabine 60 lung metastases 60 oral FTY# 60 chronic HBV infection 60 pheochromocytoma 60 BRCA mutation 60 complete remissions 60 epithelial cancers 60 PTEN gene 60 neoplasm 60 virulence genes 60 coinfection 60 SNPs 60 mutational status 60 PNH patients 60 bladder carcinoma 60 metastatic castration resistant 60 CXCL5 60 advanced NSCLC 60 Xanafide 60 uveal melanoma 60 neuroendocrine cancers 60 non squamous NSCLC 60 gastrointestinal stromal tumor GIST 60 flavopiridol 60 malignant pleural mesothelioma 60 eIF 4E 60 RRM1 60 lobular carcinoma 60 P. falciparum 60 CDKN2A 60 BRAF inhibitor 59 beta1 integrin 59 potent inhibition 59 carcinoembryonic antigen 59 medulloblastomas 59 estrogen receptor negative 59 HbF 59 prognostic variables 59 nanomolar 59 IGFBP 3 59 anti angiogenic drugs 59 susceptibility gene 59 adenoma 59 mutant allele 59 pegylated liposomal doxorubicin 59 anti angiogenic therapy 59 achieved sustained virological 59 liver metastasis 59 trastuzumab Herceptin R 59 caveolin 1 59 CpG 59 EGFR blockers 59 prognostic marker 59 SERMs 59 biochemical recurrence 59 GSTT1 59 p# activation 59 antiangiogenic agents 59 pulmonary metastases 59 lung adenocarcinoma 59 subtype 59 cancer mCRC 59 TMPRSS2 ERG 59 gemcitabine carboplatin 59 superficial bladder cancer 59 operable breast cancer 59 rs# [004] 59 CIMZIA ™ 59 colorectal cancer CRC 59 MTHFR 59 Stat5 59 seminoma 59 narcolepsy cataplexy 59 malignancies 59 neuroblastomas 59 mucinous 59 UGT#A# * 59 dasatinib Sprycel 59 castrate resistant 59 splenectomized patients 59 mutated KRAS 59 chlorambucil 59 PITX2 59 MAGE A3 protein 59 nonsense mutations 59 CDH1 59 MYH9 59 NRTI resistance 59 mRNA expression 59 Hurthle cell 59 JAK2 V#F 59 antisense inhibition 59 NF kB pathway 59 ovarian tumors 59 node metastases 59 HRPC 59 protein kinase inhibitor 59 C. pneumoniae 59 imatinib resistance 59 epithelial ovarian cancer 59 tumor xenograft models 59 T1DM 59 vandetanib 59 HBeAg 59 IDH1 mutations 59 pathogenic mutations 59 elevated triglyceride levels 59 gastric carcinogenesis 59 tarenflurbil 59 STK# [002] 59 BRCA2 mutation carriers 59 miRs 59 complete cytogenetic 59 HLA B 59 seminomas 59 histologic subtypes 59 hamartomas 59 EGFR receptor 59 FCGR3A 59 HERmark 59 endostatin 59 acute myelogenous leukemia AML 59 ccRCC 59 KIF6 gene 59 cell lymphomas 59 thyroid carcinoma 59 prognostic significance 59 imatinib Gleevec ® 59 Symadex 59 telomere lengths 59 cetuximab Erbitux 59 LQTS 59 Haptoglobin 59 preclinically 59 premalignant 59 hematopoietic cancers 59 Ceflatonin 59 APTIVUS r 59 BRAF V# mutation 59 survivin 59 PXD# 59 TNFa 59 Raf MEK ERK 59 androgen receptor AR 59 pancreatic carcinoma 59 metastatic colorectal cancer 59 anthracyclines 59 N. gonorrhoeae 59 vimentin 59 immunocompetent 59 CCX# 59 axillary lymph nodes 59 pan HDAC inhibitor 59 melatonin receptor 59 SE alleles 59 TIMP 1 59 colon tumors 59 metastatic colorectal 59 colorectal polyp 59 estrogen receptor ER 59 mCRPC 59 APOE e4 59 solid tumors 59 androgen deprivation 59 C. albicans 59 APOE ε4 59 urothelial carcinoma 59 #F FDG PET 59 VEGF receptor 59 galiximab 59 PKM2 59 HBeAg negative chronic hepatitis 59 chromosomal regions 59 MAGE A3 ASCI 59 papillary 59 hepatitis C genotype 59 MC1R gene 59 microRNA miR 59 anti leukemic 59 estrogen receptors 59 estrogen receptor 59 CCR7 59 lung nodules 59 genetic variant 59 epigenetic mechanisms 59 BRCA mutation carriers 59 riociguat 59 rs# [001] 59 HLA DRB1 * 59 #p# [001] 59 variant allele 59 T#I mutant 59 TT genotype 59 follicular lymphomas 59 benign lesions 59 FGFR 59 HCV SPRINT 59 mutant BRAF 59 mutant alleles 59 baseline LDH 59 uPAR 59 homozygotes 59 selective modulator 59 mapatumumab 59 Her2 59 bcl 2 59 TKI therapy 59 erlotinib Tarceva 59 Ki# 59 homozygous 59 LRRK2 gene 59 mutated BRAF gene 59 glioma tumors 59 relapsed ALL 59 MYH9 gene 59 unresectable stage 59 specific antigen PSA 59 metachronous 59 virologic failure 59 carcinoid tumors 59 prognostic factors 59 cediranib 59 receptor subtypes 59 #q#.# [002] 59 pro angiogenic 59 immunohistochemical analysis 59 chromosomal aberrations 59 HLA DR2 59 B CLL 59 metastatic tumors 59 TRAIL induced apoptosis 59 RASSF1A 59 anaplastic lymphoma kinase ALK 59 skeletal metastases 59 intestinal metaplasia 59 lymphocytic 59 locoregional 59 MPS IVA 59 LRP5 59 histological subtypes 59 inherited mutations 59 chromosome #q# [002] 59 herpesviruses 59 brain metastases 58 STAT3 58 imetelstat 58 atherosclerotic lesions 58 Tyrima 58 CCR2 58 HER2 gene 58 indolent NHL 58 HLA genes 58 IGFBP 58 pilocytic astrocytomas 58 LRP6 58 urine cytology 58 neoadjuvant 58 ApoE 58 osteopontin 58 chemopreventive agent 58 allele frequencies 58 SORT OUT III 58 contralateral breast cancer 58 FOLFOX4 58 cardioprotective effects 58 small lymphocytic lymphoma 58 SLC#A# [002] 58 virological response 58 p# MAPK 58 lymphoid cells 58 splice junctions 58 EndoTAGTM 1 58 BRCA1 mutation carriers 58 molecularly defined 58 invasive lobular 58 anti angiogenic agents 58 circulating endothelial cells 58 APOE allele 58 MUC1 58 Vectibix monotherapy 58 airway hyperresponsiveness 58 refractory metastatic 58 dosage regimens 58 NKG2D 58 paclitaxel eluting stents 58 EGFR pathway 58 Aurora kinase 58 depsipeptide 58 underwent surgical resection 58 DLC1 58 HLA alleles 58 chlamydial infection 58 FLT3 mutations 58 cognitively normal 58 malignant lymphoma 58 cilengitide 58 CYP#D# 58 AGTR1 58 DFMO 58 ribavirin therapy 58 chronic HCV 58 hormone refractory 58 JAK2 mutation 58 nilotinib 58 lymphovascular invasion 58 sorafenib 58 Recurrence Score 58 pancreatic NET 58 mutant KRAS 58 histologic 58 Bortezomib 58 temsirolimus 58 histologic subtype 58 CYP#D# gene 58 thalidomide Thalomid 58 standard chemotherapy regimen 58 transthyretin amyloidosis 58 FLT3 ITD 58 HNPCC 58 BCR ABL 58 miR #b [002] 58 c MET 58 orthologs 58 EGF receptors 58 autoantibody 58 stage IIIB IV 58 genotype 1a 58 gastric carcinomas 58 IFN beta 58 Squamous 58 platelet reactivity 58 tyrosine phosphorylation 58 hematopoietic cells 58 unresectable 58 neoplasias 58 TERT 58 TTR amyloidosis 58 TNF inhibitors 58 serum antibodies 58 estrogen receptor positive 58 proliferative diabetic retinopathy 58 myeloid 58 NMIBC 58 HCV genotype 1 58 TACI mutations 58 metastatic prostate 58 miRNAs 58 adjuvant therapies 58 isotype 58 conserved sequences 58 pharmacodynamic biomarkers 58 factor receptor EGFR 58 germline mutation 58 cytokeratin 58 virologic 58 tanespimycin 58 HER2 58 myeloma cells 58 miRNA expression 58 recurrent ovarian cancer 58 activin 58 stratifying patients 58 neoadjuvant therapy 58 COX2 58 CIN2 58 afatinib 58 virologic response 58 CD# + [001] 58 sustained virological response 58 MDM2 58 underlying pathophysiology 58 Velcade bortezomib 58 NPM1 mutations 58 familial amyloidotic polyneuropathy FAP 58 activating EGFR mutations 58 IV melanoma 58 metaplasia 58 sunitinib 58 metastatic disease 58 genetic determinants 58 SOD1 gene 58 invasive carcinoma 58 sentinel lymph node biopsy 58 platinum refractory 58 pT3 58 cranial irradiation 58 hematological cancers 58 #q# [002] 58 metastatic HRPC 58 taxane refractory 58 microsatellite instability 58 IgG antibodies 58 coding genes 58 unmutated 58 polycythemia vera PV 58 PI3K inhibitors 58 superinfection 58 genetic variants associated 58 adjuvant radiation 58 CCR5 delta# 58 mesothelin 58 chronic HCV infection 58 gene expression profiles 58 undetectable HBV DNA 58 genetic variations 58 H#K#me# 58 inhibitor RG# 58 haplotypes 58 IFN α 58 cellular pathways 58 Akt inhibitor 58 XmAb# 58 glioma cells 58 prognostically 58 missense mutation 58 cervical lesions 58 panitumumab Vectibix 58 meningiomas 58 steatohepatitis 58 chromosome #p# [002] 58 peptide antigens 58 hedgehog pathway 58 prospectively defined 58 IGFBP2 58 Tamibarotene 58 proteasome inhibitor 58 mGluR5 antagonist 58 serologic 58 definite stent thrombosis 58 SNP rs# [001] 58 alvespimycin 58 pancreatic lung 58 oxysterols 58 #p#.# [002] 58 pancreatic prostate 58 non mutated KRAS 58 CYP#B# 58 lupus nephritis 58 clinicopathological 58 hematologic malignancies 58 breast pancreatic 58 antitumor effect 58 AKT1 58 oblimersen 58 tumor shrinkage 58 serotonin receptor 58 alkylating agent 58 hepatic metastases 58 SSc 58 Zevalin consolidation 58 histopathological 58 pathogenic mechanisms 58 antitumor activity 58 systemic lupus erythematosus SLE 58 castration resistant 58 Hepatocellular Carcinoma HCC 58 hyperplastic 58 carcinomas 58 cytogenic 58 Leukemias 58 nodal metastasis 58 RAS mutations 58 anti EGFR antibody 58 genital tract infections 58 metastatic lung cancer 58 A3 adenosine receptor 58 chronic eosinophilic leukemia 58 differentially expressed genes 58 alkylating agents 58 dexpramipexole 58 AEG# 58 malignant nodules 58 MEK inhibitors 58 Subgroup analysis 58 APOPTONE 58 neutralizing antibody 58 HoFH 58 malignant polyps 58 carcinoembryonic antigen CEA 58 leukemic stem cells 58 PDGF receptor 58 Taxotere ® 58 Hedgehog pathway 58 acute leukemias 58 docetaxel chemotherapy 58 carotid plaques 58 unresectable tumors 58 p#INK#a 58 cell adhesion molecule 58 VEGF inhibitors 58 spontaneous mutations 58 HCV protease 58 prognostic biomarker 58 chloride secretion 58 azacitidine 58 cytologically confirmed 58 hCG beta 58 metastatic gastric 58 situ LCIS 58 PCA3 58 alleles 58 pheochromocytomas 58 DMARDs 58 peginterferon 58 lung carcinomas 58 cutaneous melanoma 58 Janus kinase 58 immunoreactivity 58 adenomatous polyps 58 familial adenomatous polyposis 58 CNVs 58 SMAD4 58 mycophenolate mofetil 58 PI3K pathway 58 LY# [003] 58 huC# DM4 58 grade gliomas 58 chemoresistance 58 breast tumors 58 hormone receptor positive 58 #q#.# [001] 58 TroVax ® 58 immunohistochemical staining 58 miR #a [002] 57 transgene expression 57 ALN TTR 57 deletion 5q 57 sunitinib Sutent 57 genotyped 57 chronic HBV 57 mammary tumors 57 c KIT 57 Tavocept 57 cytostatic 57 PC# cells 57 leukemia AML 57 axillary nodes 57 histologically confirmed 57 Randomized trials 57 HDACs 57 cTnT 57 methotrexate monotherapy